Key regions: Australia, Europe, South Africa, United States, Netherlands
The Medical Cannabis market in G20 countries is experiencing significant growth and development.
Customer preferences: Customers in G20 countries are increasingly turning to medical cannabis products due to growing awareness of their potential health benefits. There is a rising demand for natural and alternative treatment options, especially among individuals looking for solutions to chronic pain, anxiety, and other medical conditions.
Trends in the market: In the United States, the largest market for medical cannabis within the G20, there is a trend towards legalization at the state level, driving market expansion and investment. In Canada, another key player in the market, the focus is on research and development to create innovative cannabis-based pharmaceuticals. In European countries like Germany and Italy, medical cannabis is gaining acceptance and becoming more accessible to patients.
Local special circumstances: Each G20 country has its unique regulations and cultural attitudes towards medical cannabis, influencing market dynamics. For example, in Japan, where cannabis is strictly regulated, there is a growing interest in exploring the medical potential of cannabinoids while navigating strict legal boundaries. In Australia, a country with a rapidly evolving medical cannabis market, there is a focus on quality control and patient education.
Underlying macroeconomic factors: The development of the Medical Cannabis market in G20 countries is also influenced by broader macroeconomic factors. Economic growth, changing demographics, and shifting healthcare policies play a role in shaping the market landscape. Additionally, factors such as technological advancements, investment trends, and international trade agreements impact the growth and direction of the medical cannabis industry in these countries.
Data coverage:
Data encompasses B2B and B2C enterprises. Figures are based on companies' revenues, funding values and global consumer survey data. Revenues include retail, sales and taxes.Modeling approach / Market size:
Market sizes are determined by a Top-Down approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports, third-party data. Next, we use relevant key market indicators and data from country-specific associations such as tobacco spending per capita, medical product spending per capita, consumer spending and consumer spending for recreation purposes, population. This data helps us to estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function.Additional Notes:
The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
